Symptoms of rapid eye movement sleep behavior disorder are associated with cholinergic denervation in Parkinson disease
dc.contributor.author | Kotagal, Vikas | en_US |
dc.contributor.author | Albin, Roger L. | en_US |
dc.contributor.author | Müller, Martijn L. T. M. | en_US |
dc.contributor.author | Koeppe, Robert A. | en_US |
dc.contributor.author | Chervin, Ronald D. | en_US |
dc.contributor.author | Frey, Kirk A. | en_US |
dc.contributor.author | Bohnen, Nicolaas I. | en_US |
dc.date.accessioned | 2012-05-21T15:48:27Z | |
dc.date.available | 2013-06-11T19:15:52Z | en_US |
dc.date.issued | 2012-04 | en_US |
dc.identifier.citation | Kotagal, Vikas; Albin, Roger L.; Müller, Martijn L. T. M. ; Koeppe, Robert A.; Chervin, Ronald D.; Frey, Kirk A.; Bohnen, Nicolaas I. (2012). "Symptoms of rapid eye movement sleep behavior disorder are associated with cholinergic denervation in Parkinson disease." Annals of Neurology 71(4): 560-568. <http://hdl.handle.net/2027.42/91165> | en_US |
dc.identifier.issn | 0364-5134 | en_US |
dc.identifier.issn | 1531-8249 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/91165 | |
dc.description.abstract | Objective: Rapid eye movement sleep behavior disorder (RBD) is common in Parkinson disease (PD), but its relationship to the varied neurotransmitter deficits of PD and prognostic significance remain incompletely understood. RBD and cholinergic system degeneration are identified independently as risk factors for cognitive impairment in PD. We aimed to assess the association between cholinergic denervation and symptoms of RBD in PD patients without dementia. Methods: Eighty subjects with PD without dementia (age, 64.6 ± 7.0 years; range, 50–82 years; 60 males, 20 females; mean Montreal Cognitive Assessment Test [MoCA] score, 26.2 ± 2.1; range 21–30) underwent clinical assessment, neuropsychological testing, and [ 11 C]methylpiperidyl propionate acetylcholinesterase and [ 11 C]dihydrotetrabenazine (DTBZ) vesicular monoamine transporter type 2 positron emission tomography (PET) imaging. 11 C3‐Amino‐4‐(2‐dimethylaminomethyl‐phenylsulfaryl)‐benzonitrile (DASB) serotonin transporter PET imaging was performed in a subset of 35 subjects. The presence of RBD symptoms was determined using the Mayo Sleep Questionnaire. Results: Twenty‐seven of 80 subjects (33.8%) indicated a history of RBD symptoms. Subjects with and without RBD symptoms showed no significant differences in age, motor disease duration, MoCA, Unified Parkinson Disease Rating Scale motor scores, or striatal DTBZ binding. Subjects with RBD symptoms, in comparison to those without, exhibited decreased neocortical, limbic cortical, and thalamic cholinergic innervation (0.0213 ± 0.0018 vs 0.0236 ± 0.0022, t = 4.55, p < 0.0001; 0.0388 ± 0.0029 vs 0.0423 ± 0.0058, t = 2.85, p = 0.0056; 0.0388 ± 0.0025 vs 0.0427 ± 0.0042, t = 4.49, p < 0.0001, respectively). Brainstem and striatal DASB binding showed no significant differences between groups. Interpretation: The presence of RBD symptoms in PD is associated with relative neocortical, limbic cortical, and thalamic cholinergic denervation although not with differential serotoninergic or nigrostriatal dopaminergic denervation. The presence of RBD symptoms may signal cholinergic system degeneration. ANN NEUROL 2012; | en_US |
dc.publisher | Wiley Subscription Services, Inc., A Wiley Company | en_US |
dc.title | Symptoms of rapid eye movement sleep behavior disorder are associated with cholinergic denervation in Parkinson disease | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Psychiatry | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Department of Neurology, University of Michigan, and Clinic Center, Veterans Administration Ann Arbor Health System | en_US |
dc.contributor.affiliationum | Department of Neurology, University of Michigan Medical School, 2301 Commonwealth Boulevard, Room 1013, Ann Arbor, MI 48105‐2945 | en_US |
dc.contributor.affiliationum | Department of Radiology, Division of Nuclear Medicine, University of Michigan, Ann Arbor, MI | en_US |
dc.contributor.affiliationother | Neurology Service and Geriatric Research, Education, and Clinic Center, Veterans Administration Ann Arbor Health System | en_US |
dc.identifier.pmid | 22522445 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/91165/1/22691_ftp.pdf | |
dc.identifier.doi | 10.1002/ana.22691 | en_US |
dc.identifier.source | Annals of Neurology | en_US |
dc.identifier.citedreference | Ginovart N, Wilson A, Meyer J, et al. Positron emission tomography quantification of [(11)C]‐DASB binding to the human serotonin transporter: modeling strategies. J Cereb Blood Flow Metab 2001; 21: 1342 – 1353. | en_US |
dc.identifier.citedreference | Thompson CJ, Kecani S, Boelen S. Evaluation of a neck‐shield for use during neurological studies with a whole‐body PET scanner. IEEE Trans Nucl Sci 2001; 48: 1512 – 1517. | en_US |
dc.identifier.citedreference | Jewett DM, Kilbourn MR, Lee LC. A simple synthesis of [11C]dihydrotetrabenazine (DTBZ). Nucl Med Biol 1997; 24: 197 – 199. | en_US |
dc.identifier.citedreference | Innis RB, Cunningham VJ, Delforge J, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 2007; 27: 1533 – 1539. | en_US |
dc.identifier.citedreference | Snyder SE, Tluczek L, Jewett DM, et al. Synthesis of 1‐[11C]methylpiperidin‐4‐yl propionate ([11C]PMP) for in vivo measurements of acetylcholinesterase activity. Nucl Med Biol 1998; 25: 751 – 754. | en_US |
dc.identifier.citedreference | Logan J, Fowler JS, Volkow ND, et al. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab 1996; 16: 834 – 840. | en_US |
dc.identifier.citedreference | Koeppe RA, Frey KA, Kume A, et al. Equilibrium versus compartmental analysis for assessment of the vesicular monoamine transporter using (+)‐alpha‐[11C]dihydrotetrabenazine (DTBZ) and positron emission tomography. J Cereb Blood Flow Metab 1997; 17: 919 – 931. | en_US |
dc.identifier.citedreference | Koeppe RA, Frey KA, Kuhl DE, Kilbourn MR. Assessment of extrastriatal vesicular monoamine transporter binding site density using stereoisomers of [11C]dihydrotetrabenazine. J Cereb Blood Flow Metab 1999; 19: 1376 – 1384. | en_US |
dc.identifier.citedreference | Koeppe RA, Frey KA, Snyder SE, et al. Kinetic modeling of N‐[11C]methylpiperidin‐4‐yl propionate: alternatives for analysis of an irreversible positron emission tomography tracer for measurement of acetylcholinesterase activity in human brain. J Cereb Blood Flow Metab 1999; 19: 1150 – 1163. | en_US |
dc.identifier.citedreference | Postuma RB, Gagnon JF, Montplaisir J. Clinical prediction of Parkinson's disease: planning for the age of neuroprotection. J Neurol Neurosurg Psychiatry 2010; 81: 1008 – 1013. | en_US |
dc.identifier.citedreference | Gilman S, Koeppe R, Chervin R, et al. REM sleep behavior disorder is related to striatal monoaminergic deficit in MSA. Neurology 2003; 8: 29 – 34. | en_US |
dc.identifier.citedreference | Albin R, Koeppe R, Chervin R. Decreased striatal dopaminergic innervation in REM sleep behavior disorder. Neurology 2000; 55: 1410 – 1412. | en_US |
dc.identifier.citedreference | Kim YK, Yoon IY, Kim JM, et al. The implication of nigrostriatal dopaminergic degeneration in the pathogenesis of REM sleep behavior disorder. Eur J Neurol 2010; 17: 487 – 492. | en_US |
dc.identifier.citedreference | Boeve B, Silber M, Saper C, et al. Pathophysiology of REM sleep behaviour disorder and relevance to neurodegenerative disease. Brain 2007; 130 ( pt 11 ): 2770 – 2788. | en_US |
dc.identifier.citedreference | Ringman JM, Simmons JH. Treatment of REM sleep behavior disorder with donepezil: a report of three cases. Neurology 2000; 55: 870 – 871. | en_US |
dc.identifier.citedreference | Dugger BN, Murray ME, Boeve BF, et al. Neuropathological analysis of brainstem cholinergic and catecholaminergic nuclei in relation to REM sleep behaviour disorder. Neuropathol Appl Neurobiol 2011 Jun 23 [Epub ahead of print]. | en_US |
dc.identifier.citedreference | Fuller P, Sherman D, Pedersen NP, et al. Reassessment of the structural basis of the ascending arousal system. J Comp Neurol 2011; 519: 933 – 956. | en_US |
dc.identifier.citedreference | Postuma RB, Gagnon JF, Vendette M, et al. Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder. Neurology 2009; 72: 1296 – 1300. | en_US |
dc.identifier.citedreference | Kuhl DE, Koeppe RA, Minoshima S, et al. In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer's disease. Neurology 1999; 52: 691 – 699. | en_US |
dc.identifier.citedreference | Mesulam M. The cholinergic lesion of Alzheimer's disease: pivotal factor or side show? Learn Mem 2004; 11: 43 – 49. | en_US |
dc.identifier.citedreference | Boeve BF. REM sleep behavior disorder: updated review of the core features, the REM sleep behavior disorder‐neurodegenerative disease association, evolving concepts, controversies, and future directions. Ann N Y Acad Sci 2010; 1184: 15 – 54. | en_US |
dc.identifier.citedreference | Gagnon JF, Bedard MA, Fantini ML, et al. REM sleep behavior disorder and REM sleep without atonia in Parkinson's disease. Neurology 2002; 59: 585 – 589. | en_US |
dc.identifier.citedreference | Bliwise DL. Challenges in the assessment of dream enactment behavior. Sleep Med 2011; 12: 429 – 430. | en_US |
dc.identifier.citedreference | Bohnen NI, Frey KA. Imaging of cholinergic and monoaminergic neurochemical changes in neurodegenerative disorders. Mol Imaging Biol 2007; 9: 243 – 257. | en_US |
dc.identifier.citedreference | Schenck C, Bundlie S, Ettinger M, Mahowald M. Chronic behavioral disorders of human REM sleep: a new category of parasomnia. Sleep 1986; 9: 293 – 308. | en_US |
dc.identifier.citedreference | Gagnon JF, Vendette M, Postuma RB, et al. Mild cognitive impairment in rapid eye movement sleep behavior disorder and Parkinson's disease. Ann Neurol 2009; 66: 39 – 47. | en_US |
dc.identifier.citedreference | Marion MH, Qurashi M, Marshall G, Foster O. Is REM sleep behaviour disorder (RBD) a risk factor of dementia in idiopathic Parkinson's disease? J Neurol 2008; 255: 192 – 196. | en_US |
dc.identifier.citedreference | Williams‐Gray CH, Evans JR, Goris A, et al. The distinct cognitive syndromes of Parkinson's disease: 5 year follow‐up of the CamPaIGN cohort. Brain 2009; 132 ( pt 11 ): 2958 – 2969. | en_US |
dc.identifier.citedreference | Kehagia AA, Barker RA, Robbins TW. Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease. Lancet Neurol 2010; 9: 1200 – 1213. | en_US |
dc.identifier.citedreference | Braak H, Del Tredici K, Rüb U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003; 24: 197 – 211. | en_US |
dc.identifier.citedreference | Ruberg M, Rieger F, Villageois A, et al. Acetylcholinesterase and butyrylcholinesterase in frontal cortex and cerebrospinal fluid of demented and non‐demented patients with Parkinson's disease. Brain Res 1986; 362: 83 – 91. | en_US |
dc.identifier.citedreference | Bohnen NI, Kaufer DI, Ivanco LS, et al. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch Neurol 2003; 60: 1745 – 1748. | en_US |
dc.identifier.citedreference | Hilker R, Thomas AV, Klein JC, et al. Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways. Neurology 2005; 65: 1716 – 1722. | en_US |
dc.identifier.citedreference | Shimada H, Hirano S, Shinotoh H, et al. Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET. Neurology 2009; 73: 273 – 278. | en_US |
dc.identifier.citedreference | Fox SH, Chuang R, Brotchie JM. Serotonin and Parkinson's disease: on movement, mood, and madness. Mov Disord 2009; 24: 1255 – 1266. | en_US |
dc.identifier.citedreference | Albin RL, Koeppe RA, Bohnen NI, et al. Spared caudal brainstem SERT binding in early Parkinson's disease. J Cereb Blood Flow Metab 2008; 28: 441 – 444. | en_US |
dc.identifier.citedreference | Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinicopathologic study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55: 181 – 184. | en_US |
dc.identifier.citedreference | Hoehn M, Yahr M. Parkinsonism: onset, progression, and mortality. Neurology 1967; 17: 427 – 442. | en_US |
dc.identifier.citedreference | Nasreddine ZS, Phillips NA, Bedirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005; 53: 695 – 699. | en_US |
dc.identifier.citedreference | Goetz CG, Fahn S, Martinez‐Martin P, et al. Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): process, format, and clinimetric testing plan. Mov Disord 2007; 22: 41 – 47. | en_US |
dc.identifier.citedreference | Boeve BF, Molano JR, Ferman TJ, et al. Validation of the Mayo Sleep Questionnaire to screen for REM sleep behavior disorder in an aging and dementia cohort. Sleep Med 2011; 12: 445 – 453. | en_US |
dc.identifier.citedreference | Abetz L, Arbuckle R, Allen RP, et al. The reliability, validity and responsiveness of the International Restless Legs Syndrome Study Group rating scale and subscales in a clinical‐trial setting. Sleep Med 2006; 7: 340 – 349. | en_US |
dc.identifier.citedreference | Chaudhuri KR, Martinez‐Martin P. Clinical assessment of nocturnal disability in Parkinson's disease: the Parkinson's Disease Sleep Scale. Neurology 2004; 63 ( 8 suppl 3 ): S17 – S20. | en_US |
dc.identifier.citedreference | Gomez‐Esteban JC, Zarranz JJ, Tijero B, et al. Restless legs syndrome in Parkinson's disease. Mov Disord 2007; 22: 1912 – 1916. | en_US |
dc.identifier.citedreference | Nomura T, Inoue Y, Nakashima K. Clinical characteristics of Restless legs syndrome in patients with Parkinson's disease. J Neurol Sci 2006; 250: 39 – 44. | en_US |
dc.identifier.citedreference | Aarsland D, Bronnick K, Larsen JP, et al. Cognitive impairment in incident, untreated Parkinson disease: the Norwegian ParkWest study. Neurology 2009; 72: 1121 – 1126. | en_US |
dc.identifier.citedreference | Bronnick K, Alves G, Aarsland D, et al. Verbal memory in drug‐naive, newly diagnosed Parkinson's disease. The retrieval deficit hypothesis revisited. Neuropsychology 2011; 25: 114 – 124. | en_US |
dc.identifier.citedreference | Delis DC, Kramer JH, Kaplan E, Ober BA. California Verbal Learning Test manual, adult version. 2nd ed. San Antonio, TX: Psychological Corporation, 2000. | en_US |
dc.identifier.citedreference | Beatty WW, Monson N. Picture and motor sequencing in Parkinson's disease. J Geriatr Psychiatry Neurol 1990; 3: 192 – 197. | en_US |
dc.identifier.citedreference | Wechsler D. WAIS III technical manual. San Antonio, TX: Psychological Corporation, 1997. | en_US |
dc.identifier.citedreference | Delis DC, Kaplan E, Kramer JH. Delis‐Kaplan Executive Function System (D‐KEFS): examiner's manual. San Antonio, TX: Psychological Corporation, 2001. | en_US |
dc.identifier.citedreference | Schmitt FA, Farlow MR, Meng X, et al. Efficacy of rivastigmine on executive function in patients with Parkinson's disease dementia. CNS Neurosci Ther 2010; 16: 330 – 336. | en_US |
dc.identifier.citedreference | Stroop JR. Studies of interference in serial verbal reactions. J Exp Psychol 1935; 18: 643 – 662. | en_US |
dc.identifier.citedreference | Bohnen NI, Jolles J, Twijnstra A. Modification of the Stroop Color Word Test improves differentiation between patients with mild head injury and matched controls. Clin Neuropsychol 1992; 6: 178 – 184. | en_US |
dc.identifier.citedreference | Woodward TS, Bub DN, Hunter MA. Task switching deficits associated with Parkinson's disease reflect depleted attentional resources. Neuropsychologia 2002; 40: 1948 – 1955. | en_US |
dc.identifier.citedreference | Bohnen NI, Muller ML, Kotagal V, et al. Olfactory dysfunction, central cholinergic integrity and cognitive impairment in Parkinson's disease. Brain 2010; 133 ( pt 6 ): 1747 – 1754. | en_US |
dc.identifier.citedreference | Galtier I, Nieto A, Barroso J, Norelis Lorenzo J. Visuospatial learning impairment in Parkinson disease [in Spanish]. Psicothema 2009; 21: 21 – 26. | en_US |
dc.identifier.citedreference | Benton AL, Varney NR, Hamsher K. Judgment of line orientation, form V. Iowa City, IA: University of Iowa Hospitals, 1975. | en_US |
dc.identifier.citedreference | Vander Borght TM, Sima AA, Kilbourn MR, et al. [3H]methoxytetrabenazine: a high specific activity ligand for estimating monoaminergic neuronal integrity. Neuroscience 1995; 68: 955 – 962. | en_US |
dc.identifier.citedreference | Wilson JM, Levey AI, Rajput A, et al. Differential changes in neurochemical markers of striatal dopamine nerve terminals in idiopathic Parkinson's disease. Neurology 1996; 47: 718 – 726. | en_US |
dc.identifier.citedreference | Frey KA, Koeppe RA, Kilbourn MR. Imaging the vesicular monoamine transporter. Adv Neurol 2001; 86: 237 – 247. | en_US |
dc.identifier.citedreference | Bohnen NI, Albin RL. The cholinergic system and Parkinson disease. Behav Brain Res 2011; 221: 564 – 573. | en_US |
dc.identifier.citedreference | Shute CC, Lewis PR. Electron microscopy of cholinergic terminals and acetylcholinesterase‐containing neurones in the hippocampal formation of the rat. Z Zellforsch Mikrosk Anat 1966; 69: 334 – 343. | en_US |
dc.identifier.citedreference | Meyer J. Imaging the serotonin transporter during major depressive disorder and antidepressant treatment. J Psychiatry Neurosci 2007; 32: 86 – 102. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.